Perspectives

A Deadly Thrombotic Microangiopathy Syndrome without Schistocytosis

Authors: Biplab K. Saha, MD

Abstract

Establishing a diagnosis of thrombotic microangiopathy (TMA) is not always straightforward, and significant vigilance and a low threshold of suspicion are necessary on the part of the clinician. A delayed or misdiagnosis may result in patient harm in the form of organ failure or even death. TMA is clinically diagnosed by the presence of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and end-organ dysfunction.1
Posted in: Hematology9

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654-666.
 
2. Gavriilaki E, Sakellari I, Anagnostopoulos A, et al. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone Marrow Transplant 2017;52:1355–1360.
 
3. Nakamae H, Yamane T, Hasegawa T, et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81:525-531.
 
4. Willems E, Baron F, Baudoux E, et al. Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia 2009;23:608-610.
 
5. Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006;82:638-644.
 
6. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013;122:2003–2007.
 
7. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007;92:95-100.
 
8. Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:976-984.
 
9. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling Ariadne’s thread into the labyrinth of complement therapeutics. Front Immunol 2019;10:337.
 
10. Cataland SR, Holers VM, Geyer S, et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014;123:3733–3738.
 
11. Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–575.
 
12. Saha BK, Saha A, Chong W, et al. A fatal case of thrombotic microangiopathy without schistocytosis and absent biochemical markers of hemolysis. Am J Med Sci 2020;359:296-302.
 
13. Cho B-S, Yahng S-A, Lee S-E, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010;90:918–926.
 
14. Changsirikulchai S, Myerson D, Guthrie KA, et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009;4:345–353.
 
15. Laskin BL, Goebel J, Davies SM, et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011;118:1452–1462.
 
16. Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr 2019;7:133.
 
17. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006;17:1995–2005.